Travis Whitfill
Gründer bei AZITRA, INC.
Vermögen: 73 590 $ am 30.04.2024
Profil
Mr. Travis Whitfill is an Independent Director at IN8bio, Inc., a Partner at BIOS Equity Partners LP and a Chief Operating Officer & Director at Azitra, Inc. He is on the Board of Directors at IN8bio, Inc. and Azitra, Inc. Mr. Whitfill was previously employed as a Partner by BIOS Capital Management LP.
He also served on the board at SIRPant Immunotherapeutics, Inc., 410 Medical, Inc. and Immusoft Corp.
He received his undergraduate degree from Dallas Baptist University, a graduate degree from Yale University and a graduate degree from the University College London.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
AZITRA INC
1,16% | 31.03.2024 | 334 501 ( 1,16% ) | 73 590 $ | 30.04.2024 |
Aktive Positionen von Travis Whitfill
Unternehmen | Position | Beginn |
---|---|---|
AZITRA, INC. | Gründer | 02.01.2014 |
IN8BIO, INC. | Direktor/Vorstandsmitglied | 07.05.2018 |
BIOS Equity Partners LP
BIOS Equity Partners LP Investment ManagersFinance Part of BIOS Capital Management LP, BIOS Equity Partners LP functions as a private equity firm. The company is based in Texas. The American company was founded by Leslie W. Kreis. | Corporate Officer/Principal | 01.10.2015 |
Ehemalige bekannte Positionen von Travis Whitfill
Unternehmen | Position | Ende |
---|---|---|
BIOS Capital Management LP
BIOS Capital Management LP Investment ManagersFinance BIOS Capital Management LP (BIOS Partners) is a venture capital firm founded in 2014 by Stella Robertson, Aaron Fletcher and Leslie Kreis. The firm is headquartered in Fort Worth, Texas. | Private Equity Investor | 01.06.2023 |
SIRPant Immunotherapeutics, Inc.
SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki. | Direktor/Vorstandsmitglied | 01.06.2023 |
410 Medical, Inc.
410 Medical, Inc. Medical SpecialtiesHealth Technology 410 Medical, Inc. operates as a medical device company. It develops LifeFlow for fluid resuscitation to help patients with life-threatening illnesses such as sepsis. The company was founded by Mark Donald Piehl and Luke Miller Roush in 2013 and is headquartered in Durham, NC. | Direktor/Vorstandsmitglied | 01.07.2019 |
Immusoft Corp.
Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Direktor/Vorstandsmitglied | - |
Ausbildung von Travis Whitfill
Dallas Baptist University | Undergraduate Degree |
Yale University | Graduate Degree |
University College London | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
AZITRA, INC. | Health Technology |
IN8BIO, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
BIOS Capital Management LP
BIOS Capital Management LP Investment ManagersFinance BIOS Capital Management LP (BIOS Partners) is a venture capital firm founded in 2014 by Stella Robertson, Aaron Fletcher and Leslie Kreis. The firm is headquartered in Fort Worth, Texas. | Finance |
410 Medical, Inc.
410 Medical, Inc. Medical SpecialtiesHealth Technology 410 Medical, Inc. operates as a medical device company. It develops LifeFlow for fluid resuscitation to help patients with life-threatening illnesses such as sepsis. The company was founded by Mark Donald Piehl and Luke Miller Roush in 2013 and is headquartered in Durham, NC. | Health Technology |
BIOS Equity Partners LP
BIOS Equity Partners LP Investment ManagersFinance Part of BIOS Capital Management LP, BIOS Equity Partners LP functions as a private equity firm. The company is based in Texas. The American company was founded by Leslie W. Kreis. | Finance |
SIRPant Immunotherapeutics, Inc.
SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki. | Health Technology |
Immusoft Corp.
Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Health Services |